AstraZeneca is moving to sell its 64-acre manufacturing facility in Bengaluru for Rs 3,400 crore as part of a broader strategy to streamline operations and enhance its financial outlook. This decision arrives amidst scrutiny over potential kickbacks in Brazil’s vaccine procurement, though the company’s strong oncology pipeline and anticipated revenue growth to $80 billion by 2030 suggest resilience. Analysts believe AstraZeneca remains undervalued, with advancements in artificial intelligence and key drug launches expected to drive future success despite ongoing challenges from generics and drug pricing pressures.
“AZN is cheap given its growth prospects. Analysts view their pipeline of new drugs as the best in the biopharma industry.”
“AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 crore”
“Yes, kickbacks from pharma to officials are a documented risk in Brazil's vaccine procurement—Senate probes exposed demands for bribes in 2021 Covaxin and AstraZeneca deals under Bolsonaro, leading to suspensions and investigations.”
“No direct evidence links it to kickbacks, but high-stakes contracts always invite scrutiny for influence.”
“@AstraZeneca apuesta por la inteligencia artificial y los datos para transformar la salud: detectar enfermedades antes de los síntomas, mejorar tratamientos y aliviar la presión de los sistemas.”
“AstraZeneca Pharma gets permission to import for sale of Acalabrutinib tablets in India”
“AZN als Wachstumsmaschine ist mein Favorit, wegen Pipeline und Diversifikation.”
“The Indian unit of the Bio Pharma company AstraZeneca is planning to sell its 64-acre manufacturing facility in North Bengaluru, as part of a review of its global manufacturing and supply network.”
“ASTRAZENECA PHARMA: CO BAGS CDSCO NOD FOR CALQUENCE(ACALABRUTINIB) ADDITIONAL INDICATION || NEW APPROVAL COVERS TREATMENT OF PREVIOUSLY UNTREATED CLL/SLL IN INDIA”
“AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 crore”
“$AZN Interesting discovery. Street is modeling AVANZAR delay as a risk. But it is likely due to 'robust estimates for the control arm' which can flip the sentiment quickly into a potential positive catalyst surprise in mid-2026.”
“Dès le 19.02.2021 et à plusieurs reprises également lors des réunions suivantes, le comité de crise de Cologne a noté que le vaccin d’AstraZeneca nécessitait une « réhabilitation médiatique » sur le plan de la communication...”